Retina

NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability, and preliminary efficacy of a single intravitreal injection of SPVN20 over 6 months.

Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

Catch up on news you may have missed at the meeting in Orlando, like the effects of GLP-1 drugs on eye health and a potential sign of cardiovascular disease.

David Eichenbaum, MD, FASRS, recalls an early-career case managing bilateral diabetic macular edema with frequent intravitreal triamcinolone injections—leading to severe steroid-induced glaucoma and valve implants.

REMAIN is the long-term extension of the phase 2b/3 RESTORE trial evaluating MCO-010 in retinitis pigmentosa (RP).

HELIOS Phase 1 showed consistent reductions in retinal fluid with OTX-TKI, paving the way for pivotal HELIOS-2 and HELIOS-3 trials.

A study reveals that systemic chemotherapy significantly reduces mortality in retinoblastoma, while targeted treatments lower enucleation rates.

New research reveals subretinal drusenoid deposits in Black and Hispanic AMD patients may signal higher vascular disease risk

Optogenetics shows promise in improving mobility and object recognition for patients with retinitis pigmentosa and Stargardt disease.

SriniVas R. Sadda, MD, FARVO, recalls a residency case that highlights the transformative impact of OCT and OCT angiography.

The CNPV program was announced by the FDA in June 2025 and offers companies the opportunity to reduce standard application review times from 10–12 months to just 1–2 months.

According to the company, FALCON aimed to provide “a better understanding of how autosomal dominant optic atrophy (ADOA) disease parameters change over time to inform potential future interventional clinical trials.”

In the Phase 2 TEASE 2 trial, gildeuretinol was well tolerated and showed promising trends in slowing ellipsoid zone loss and preserving low-luminance visual acuity in patients with Stargardt disease.

The 18-month extension of the GATHER2 trial indicated continued benefit for patients receiving avacincaptad pegol, with efficacy gains increasing over time.

Durga Borkar, MD, MMCi, explores real-world treatment patterns and safety of avacincaptad pegol for geographic atrophy, revealing critical insights for patient care.

Explore groundbreaking advancements in eye care from the 2000s, including LASIK innovations, anti-VEGF treatments, and enhanced imaging technologies.

The FDA describes the RDEA pilot program as a program to support novel endpoint efficacy development for drugs that treat rare diseases.

EYDENZELT is Celltrion's first FDA-approved biologic product in ophthalmology.

A recent study uncovers a novel biomarker for retinal vascular diseases, highlighting the significance of intermittent capillary perfusion in monitoring treatment efficacy.

The procedure showed positive effects on the electroretinography (ERG) (b-wave, oscillatory potentials), optomotor response, and contrast sensitivity in actively treated eyes compared with controls.

NPI-001 is Nacuity’s investigational therapy for the treatment of patients with retinitis pigmentosa (RP).